Advertisement

Monoclonal Antibodies

  • Christopher Dean
  • Helmout Modjtahedi
Protocol
  • 1k Downloads
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

Like all great discoveries, the procedure developed by George Kohler and Cesar Milstein for immortalizing antibody producing B-lymphocytes (1) is essentially simple, namely, mix B-lymphocytes from the spleen of an immunized rodent with a continuously proliferating B-lymphoma cell line, then induce their membranes to fuse to give a single antibody-secreting cell (hybridoma) that will proliferate indefinitely Importantly, each hybndoma will secrete antibodies with a specificity for only one antigenic epitope, I e., the antibodies are monoclonal It is this property, together with the ability to produce unlimited amounts of antibody, that has revolutionized the use of antibodies in many areas of biological and medical research, and has found important applications not only in clinical diagnosis and therapy, but also for large-scale purification of biological materials Indeed, monoclonal antibodies (MAbs) are essential tools for the cell and molecular biologist and their use has unlocked the doors behind which the function of many proteins and other cellular molecules would have lain hidden

Keywords

Myeloma Cell Rabbit MAbs DE52 Cellulose Immune Lymph Node Fatty Connective Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kohler, G and Milstein, C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity Nature (London) 256, 495–497CrossRefGoogle Scholar
  2. 2.
    Galfré, G and Milstein, C (1981) Preparation of monoclonal antibodies: strategies and procedures, in Methods in Enzymology, vol 73, Immunochemical Techniques (Langone, J J. and Van Vunakis, H, eds), Academic, New York, pp 3–46Google Scholar
  3. 3.
    Bazin, H (1982) Production of rat monoclonal antibodies with the LOU rat non-secreting IR983F myeloma cell line, in Protides of the Biologcal Fluids, 29th Colloquium (Peeters, H, ed), Pergamon, New York, pp 615–618Google Scholar
  4. 4.
    Edwards, P A W, Smith, C M, Neville, A M, and O’Hare, M J (1982) A humanhuman hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukaemia-derived line Eur J Immunol 12, 641–648PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson, D V, Tucker, E M, Powell, J R, and Porter, P (1987) Bovine monoclonal antibodies to the FS (K99) pilus antigen of E coh produced by munne/bovine hybridomas Vet Immunol Immunopathol 15, 223–237PubMedCrossRefGoogle Scholar
  6. 6.
    Flynn, J N, Harkiss, G D, and Hopkins, J (1989) Generation of a sheep × mouse heterohybndoma cell line (1C6 3a6T 1D7) and evaluation of its use in the production of ovine monoclonal antibodies J Immunol Meth 121, 237–246CrossRefGoogle Scholar
  7. 7.
    Richards, C M, Aucken, H A, Tucker, E M, Hannant, D, Mumford, J A, and Powell, J R (1992) The production of equine monoclonal antibodies by horse—mouse heterohybndomas Vet Immunol Immunopathol 33, 129–143PubMedCrossRefGoogle Scholar
  8. 8.
    Spieker-Polet, H, Sethupathi, P, Yam, P-C, and Knight, K L (1995) Rabbit monoclonal antibodies generating a fusion partner to produce rabbit—rabbit hybndomas Proc Natl Acad Sci USA 92, 9348–9352PubMedCrossRefGoogle Scholar
  9. 9.
    Dean, C J (1984) Preparation and characterization of monoclonal antibodies to proteins and other cellular components, in Methods in Molecular Biology, vol 32 Basic Protein and Peptide Protocols (Walker, J M, ed), Humana, Totowa, NJ, pp 361–379Google Scholar
  10. 10.
    Gullick, W J (1984) Production of antisera to synthetic peptides, in Methods in Molecular Biology, vol 32 Basic Protein and Peptide Protocols (Walker, J M, ed), Humana, Totowa, NJ, pp 389–399Google Scholar
  11. 11.
    Taylor-Papadimitnou, J, Stewart, L, Burchell, J, and Beverley, P (1993) The polymorphic epithelial mucin as a target for immunotherapy Ann NY Acad Sci 690, 69–79CrossRefGoogle Scholar
  12. 12.
    Dean, C J, Styles, J M, Gyure, L A, Peppard, J, Hobbs, S M, Jackson, E, and Hall, J G (1984) The production of hybndomas from the gut-associated lymphoid tissue of tumour-bearing rats I Mesenteric nodes as a source of IgG producing cells Clin Exp Immunol 57, 358–364PubMedGoogle Scholar
  13. 13.
    Harlow, E and Lane, D P (1988) Antibodies, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NYGoogle Scholar
  14. 14.
    Modjtahedi, H, Styles, J M, and Dean, C J (1993) The human EGF receptor as a target for cancer therapy six new rat antibodies against the receptor on the breast carcinoma MDA-MB 468 Br J Cancer 67, 247–253PubMedCrossRefGoogle Scholar
  15. 15.
    Styles, J M, Harrison, S, Gusterson, B A, and Dean, C J (1990) Rat monoclonal antibodies to the extracellular domain of the product of the c-erbB-2 proto-oncogene Int J Cancer 45, 320–324PubMedCrossRefGoogle Scholar
  16. 16.
    Modjtahedi, H, Eccles, S, Box, G, Styles, J, and Dean, C (1993) Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block gowth factor—receptor interaction Br J Cancer 67, 254–261PubMedCrossRefGoogle Scholar
  17. 17.
    Modjtahedi, H, Hickish, T, Nicolson, M, Moore, J, Styles, J, Eccles, S, Jackson, E, Salter, J, Sloane, J, Spencer, L, Priest, K, Smith, I, Dean, C, and Gore, M (1996) Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer Br J Cancer 73, 228–235PubMedCrossRefGoogle Scholar
  18. 18.
    Eccles, S A, Court, W J, Box, G A, Dean, C J, Melton, R J, and Springer, C J (1994) Regression of established breast carcinoma xenografts with antibody directed enzyme prodrug therapy (ADEPT) against c-erbB2 p 185 Cancer Res 54, 5171–5177PubMedGoogle Scholar
  19. 19.
    Modjtahedi, H and Dean, C (1994) The receptor for EGF and its ligands expression, prognostic value and target for therapy in cancer (review) Int J Cancer 4, 277–296Google Scholar
  20. 20.
    Hynes, N E and Stern, D F (1994) The biology of erbB-2/neu/HER-2 and its role in cancer Biochim Biophys Acta 1198, 165–184PubMedGoogle Scholar
  21. 21.
    Bernaid, A (1984) Leukocyte Typing Human Leucocyte Differentiation Antigens Detected by Monoclonal Antibodies Specification, Classification, Nomenclature Spnnger-Verlag, BerlinGoogle Scholar
  22. 22.
    Barclay, A N, Brown, M H, Law, A, McKnight, A J, Tomlenson, M, Anton vander Mewe, P (1997) The Leucocyte Antigen Facts Book Academic, London, UKGoogle Scholar
  23. 23.
    Rock, K L (1996) A new foreign policy MHC class I molecules monitor the outside world Immunol Today 17, 131–137PubMedCrossRefGoogle Scholar
  24. 24.
    Goldstein, G, Schindler, J, Tsai, H, et al (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants N Engl J Med 313, 337–342CrossRefGoogle Scholar
  25. 25.
    Waldmann, H and Cobbold, S (1993) The use of monoclonal antibodies to achieve lmmunological tolerance Immunol Today 14, 247–251PubMedCrossRefGoogle Scholar
  26. 26.
    Harris, W J and Cunnngham, C (1995) Antibody Therapeutics R G Landes, Austin, TXGoogle Scholar
  27. 27.
    Press, O W, Eary, J F, Appelbaum, F R, Martin, P J, Badger, C C, Nelp, W B, Glenn, S, Butchko, G, Fisher, D, Porter, B, Mathews, D C, Fisher, L D., and Bernstein, I D (1993) Radiolabelled antibody therapy of B cell lymphoma with autologous bone marrow support N EnglJ Med 329, 1219–1224CrossRefGoogle Scholar
  28. 28.
    Hird, V, Maraveyas, A, Snook, D, Dhokia, B, Soutter, W P, Meares, C, Stewart, J, Mason, P, Lambert, H, and Epenetos, A (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody Br J Cancer 68, 403–406PubMedCrossRefGoogle Scholar
  29. 29.
    Reithmuller, G, Schneider-Gadicke, E, Schlimok, G, Schmiegel, W, Raab, R, Pichlmair, H, Hirche, H, Pichlmayr, R, Buggisch, P, Witte, J, and the German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma Lancet 343, 1177–1183CrossRefGoogle Scholar
  30. 30.
    Jones, P T, Dear, P H, Foote, J, Neuberger, M S, and Winter, G (1986) Replacing the complementarity determining regions in a human antibody with those from a mouse Nature 321, 522–525PubMedCrossRefGoogle Scholar
  31. 31.
    Winter, G, Griffiths, A D, Hawkins R E, et al (1994) Making antibodies by phage display technology Ann Rev Immunol 12, 433–455CrossRefGoogle Scholar

Copyright information

© Humana Press Inc , Totowa, NJ. 1998

Authors and Affiliations

  • Christopher Dean
    • 1
  • Helmout Modjtahedi
    • 1
  1. 1.Section of ImmunologyInstitute of Cancer Research, McElwatn LaboratoriesUK

Personalised recommendations